Nanotechnology Databases

Comprehensive databases for nanomaterials, events, products,
companies, research labs, degree programs and publications

 

Nanobiotechnology and Nanomedicine Companies

 

Showing results 1 - 20 of 48 for companies in category Delivery in USA:

 
The company's nab™ drug delivery technology uses albumin nanoparticles to deliver drugs into tumors.
Access' lead anticancer program is ProLindac™ applies the principals of nanoparticulate prodrugs to enhance the delivery of a platinum drug to tumors.
The company has developed a proprietary formulation technology called HDDS that converts drugs that do not dissolve well in water, or hydrophobic drugs, into microparticles or nanoparticles of the drug embedded in small microspheres, such that the drug can more rapidly dissolve in water.
Designs, engineers and fabricates coatings, capsules, and "Artificial Cells" from polymers called polypeptides by a method called layer-by-layer self-assembly (LBL).
A biotechnology company engaged in the development and delivery of novel protein and cellular based therapies through design of proprietary Biological Nano Particles.
A specialty pharmaceutical company with a novel drug delivery system. Its proprietary Protein Stabilized Liposomes nanotechnology platform addresses the significant problems associated with delivery of water insoluble drugs.
The company's he Bioral® drug delivery technology encapsulates the selected drug in a nanocrystalline structure termed a "cochleate" cylinder.
Develops amphiphilic self-assembling nanocapsules and planar membranes for drug delivery.
The company's Bioral drug delivery technology encapsulates the selected drug in a nanocrystalline structure termed a 'cochleate' cylinder. All of the components of the cochleate cylinder are naturally occurring substances. It is believed that the cochleate cylinder provides an effective delivery mechanism without forming a chemical bond, or otherwise chemically altering, the selected drug.
Develops nanotechnology drug delivery systems based on novel nanomaterials that provide precise control over location and timing of drug delivery.
Calando combines proprietary technologies in targeted polymeric nanoparticle delivery systems and siRNA design to create effective therapeutics.
The company develops nanoparticle-based gene therapies for eye disease.
Developed a technology to compact DNA into complexes containing only a single molecule of DNA, resulting in a volume 30-1000 times smaller than other complexes. This simple difference makes Copernicus' "DNA nanoparticles" highly stable and uniquely able to deliver DNA to the nuclei of non-dividing human cells - which includes most cells in the body.
Develops the Emulsiphan™ nanoparticle tumor targeting technology.
The Company is developing a pipeline of multifunctional, next-generation therapeutics, binding known anti-cancer agents to its patented colloidal gold tumor-targeting nanotechnology.
Delpor develops the next generation Drug Delivery Systems that improve the clinical and commercial value of drugs and biopharmaceuticals. The company also has developed a microfabricated nanopore device for the sustained release of therapeutic agents.
The company is focused on the use of fullerene carbon nanotubes for novel therapeutic applications specifically in the area of cancer treatment. The company's extensive carbon nanotube-related, worldwide intellectual property portfolio includes discoveries by the late Nobel Prize winner Dr Rick Smalley. The use of fullerene carbon nanotubes has the goal of solving two important problems for many cancer therapeutics, that of delivering large active agents into the desired location and of protecting normal tissue from the active agent during delivery.
The company's targeted nanocapsule technology is designed using a flexible formulation process and can carry large or small molecules, custom target delivery to different organs, tissues and cells, and be applied several ways including topically, intravenously, or via devices or tablets.
The company is developing therapeutic immunotherapy by incorporating virus-specific immunogenic DNA into nanoparticles.
iCeutica has developed the Encapsulated Organic Nanoparticles (EON™) Platform to produce consistent nano-sized drug particles.
 
 
left arrowBack to Nanotechnology Links Directory